key: cord-0981890-kmqco9l1
authors: Homayounieh, Fatemeh; Holmberg, Ola; AL Umairi, Rashid; Aly, Sallam; Basevičius, Algidas; Costa, Paulo Roberto; Darweesh, Adham; Gershan, Vesna; Ilves, Pilvi; Kostova-Lefterova, Desislava; Renha, Simone Kodlulovich; Mohseni, Iman; Rampado, Osvaldo; Rotaru, Natalia; Shirazu, Issahaku; Sinitsyn, Valentin; Turk, Tajana; Van Ngoc Ty, Claire; Kalra, Mannudeep K.; Vassileva, Jenia
title: Variations in CT Utilization, Protocols, and Radiation Doses in COVID-19 Pneumonia: Results from 28 Countries in the IAEA Study
date: 2020-11-10
journal: Radiology
DOI: 10.1148/radiol.2020203453
sha: 1169516f57281a5364b51e00c48111562c0b5a13
doc_id: 981890
cord_uid: kmqco9l1

BACKGROUND: There is lack of guidance on specific CT protocols for imaging patients with coronavirus disease 2019 (COVID-19) pneumonia. PURPOSE: To assess international variations in CT utilization, protocols, and radiation doses in patients with COVID-19 pneumonia. MATERIALS AND METHODS: In this retrospective data collection study, the International Atomic Energy Agency (IAEA) coordinated a survey between May and July 2020 regarding CT utilization, protocols, and radiation doses from 62 healthcare sites in 34 countries across five continents for CT exams performed in COVID-19 pneumonia. The questionnaire obtained information on local prevalence, method of diagnosis, most frequent imaging, indications for CT, and specific policies on use of CT in COVID-19 pneumonia. Collected data included general information (patient age, weight, clinical indication), CT equipment (CT make and model, year of installation, number of detector rows), scan protocols (body region, scan phases, tube current and potential), and radiation dose descriptors (CT dose index (CTDI(vol)) and dose length product (DLP)). Descriptive statistics and generalized estimating equations were performed. RESULTS: Data from 782 patients (median age (interquartile range) of 59(15) years) from 54 healthcare sites in 28 countries were evaluated. Less than one-half of the healthcare sites used CT for initial diagnosis of COVID-19 pneumonia and three-fourth used CT for assessing disease severity. CTDI(vol) varied based on CT vendors (7-11mGy, p<0.001), number of detector-rows (8-9mGy, p<0.001), year of CT installation (7-10mGy, p=0.006), and reconstruction techniques (7-10mGy, p=0.03). Multiphase chest CT exams performed in 20% of sites (11 of 54) were associated with higher DLP compared with single-phase chest CT exams performed in 80% (43 of 54 sites) (p=0.008). CONCLUSION: CT use, scan protocols, and radiation doses in patients with COVID-19 pneumonia showed wide variation across healthcare sites within the same and different countries. Many patients were scanned multiple times and/or with multiphase CT scan protocols. See also the editorial by Lee.

Beyond healthcare, the coronavirus disease 2019 (COVID- 19) pandemic has rippled the financial and social wellbeing of the wealthiest to the most underprivileged sections and parts of the world [1] [2] [3] [4] [5] . Most healthcare and government policymakers agree that screening of both suspected and asymptomatic population with early isolation, contact tracing, and quarantine slows the transmission of this highly contagious virus [6, 7] . But disparities exist in the availability of the preferred diagnostic test, reverse transcription polymerase chain reaction (RT-PCR) for COVID- 19 . Also, the high false-negative rate of RT-PCR in early disease and its inability to assess disease severity and progression have led to the growing use of cross-sectional imaging such as CT for diagnosis and assessing disease severity, progression, complications, and treatment response [8] . Although a few single-center studies reported use of chest CT for diagnosis and work-up of patients with COVID-19 pneumonia [9, 10] , a recent survey suggested that only a very few sites use reduced-dose scan protocols (with lower radiation dose compared to routine or general chest CT protocol) for imaging patients with the suspected or known disease [8] . Despite reports on chest radiography and non-ionizing radiation-based imaging with ultrasonography [11, 12] , CT remains the preferred imaging modality in COVID-19 pneumonia.

Because >95% of patients with COVID-19 infection survive and the use of X-ray radiation-based CT is high, it is important to understand the utilization of CT and its associated radiation doses in different institutions. To our knowledge, there are no comprehensive studies on CT utilization, scan protocols, and radiation doses on an international level in patients with COVID-19 infection. Therefore, the Radiation Protection of Patients unit of the International Atomic Energy Agency (IAEA) coordinated a study of CT use in patients with pneumonia. The purpose of this study was to assess international variations in CT utilization, I n P r e s s protocols, and radiation doses in patients with coronavirus disease 2019 (COVID- 19) pneumonia.

The participating healthcare sites shared fully anonymized data on patients with COVID-19 pneumonia in compliance with their institutional review boards. Human Insurance Portability and Accountability Act (HIPAA) was not applicable as there was no patient or scan data from the United States. Only de-identified data were collected as part of a voluntary survey coordinated by the IAEA. To ensure maximum patient privacy since some parts of the world had very few cases, we did not capture information on patient gender. The requirement for obtaining informed consent was waived. None of the coauthors have any financial disclosures related to the study. One study coauthor (MKK) has received research grants from Siemens Healthineers and Riverain Tech and serves on the medical advisory board of Globus Medical Inc. (Danvers, MA) for unrelated research projects.

The two-part survey included a questionnaire and fillable form for scan parameters and doserelated information in patients with known or suspected COVID-19 pneumonia. A medical physicist, CT technologist, and/or radiologist filled the survey details. In the questionnaire, we requested participating healthcare sites to answer the following twelve questions: We requested the healthcare sites with use of CT in COVID-19 infection to provide the following de-identified information: clinical details (patient age in years, body weight in kilograms, and clinical indications for each CT), CT scanner information (name of hospital with the CT scanner, scan vendor, scanner name, number of detector-rows, and year of installation), scan parameters (number of scan phases, body region, scan start and end locations, helical or axial scan mode, use of fixed tube current vs automatic exposure control (AEC), applied tube current or vendor-specific image quality parameter for AEC, tube potential, detector configuration, pitch, gantry rotation time, reconstructed section thickness of prospective or initial transverse CT images , and filtered back-projection or iterative reconstruction technique), and radiation dose descriptors (separate volume CT dose index -CTDIvol and dose length product -DLP for each acquired phase in healthcare sites with multiphase scan protocols). For multiphase CT protocols, specific type of phase with and without contrast enhancement were recorded (such as non-contrast, post-contrast arterial, venous, and/or delayed phases). For each phase, we I n P r e s s instructed the participating healthcare sites to provide separate CTDIvol and DLP values. For patients with more than one CT examination, clinical, scan parameters and dose-related information were recorded separately for each exam.

One radiologist (MKK with >15 years of experience in CT radiation dose research) and 

Each participating hospital was requested to provide the above-mentioned fillable information on at least 10-20 adult patients, who underwent CT with a suspected or known COVID-19 pneumonia. To avoid data truncation and assess CT usage in each patient, we requested sites to provide data on all initial and follow-up CT exams since their suspected or known COVID-19 pneumonia. Sites from countries (8 sites from 6 countries) with less than 10 patients were excluded from the data analyses. Since very few sites (5/34 sites; <5% of the data) provided information related to CT examination of body regions other than chest, to obtain statistically meaningful data, statistical analysis was limited to only chest CT exams. and ≥80 years). A p-value less than 0.05 was considered as a statistically significant difference.

Responses to survey questionnaire from 62 healthcare sites from 34 countries are summarized in 

De-identified data from 782 patients (median age (IQR) of 59(15) years) was collected from 54 healthcare sites in 28 countries (Figure 1 ). There were 8-fold variations in median CTDIvol and 10-fold variations in median DLP across multiple participating healthcare sites from the same country (Table 1) . Most patients underwent a single CT examination (71%; 557/782). Extent of change in CTDIvol and DLP with the number of CT examinations per patient is summarized in Table 2 .

There were no differences in the median CTDIvol (8-9mGy; p=0.41) and DLP (299-344mGy.cm; p=0.84) between chest CT examinations performed in different continents (Table   3) . But due to frequency of multiple follow-up chest CT, cumulative DLPs for patients in Latin America (503 mGy.cm) was higher compared with the corresponding values from the other three continents (306-382 mGy.cm) (p=0.03).

Both median CTDIvol (7-11mGy, p<0.001) and DLP (280-439mGy.cm, p=0.018) differed across CT scanners from the four major vendors (Table 3) Table 3) .

Scanners with >64-detector-rows were associated with lower CTDIvol (8-9mGy; p<0.001) and median DLP (285-334mGy.cm; p=0.002) as compared with those with ≤64-detector-rows. Median CTDIvol for single-and multiple-phase chest CT were significantly different due to change in acquisition parameters such as tube current for delayed phase as compared to initial non-contrast and arterial phases (single-phase-8mGy; multiple-phase-6mGy; p<0.001). Median DLP values was lower with a single phase (315mGym.cm) to three scan phases (1310mGy.cm, p=0.008). Radiation doses for single-and multi-phase chest CT exams are summarized in Figure   3 . Single-phase, non-contrast chest CT was the most commonly reported protocol in 24/28 countries (43/54 healthcare sites), whereas multiphase CT were performed in 4/28 countries (11/54 healthcare sites). Only one hospital (1/54) acquired dual-phase contrast enhanced CT in arterial and venous phases without the non-contrast phase. There was no difference in CTDIvol I n P r e s s (8-9mGy) across non-contrast, arterial, venous, and delayed phases (p=0.0.61) although median DLP values varied (300-386mGy.cm) (p=0.041) (Figure 4 ).

Our study on variations in CT utilization, protocols, and radiation doses demonstrates a lack of guidance on CT protocols contributing to variable CT practices in COVID-19 pneumonia across different healthcare sites. CT was most often used to assess disease severity and less commonly for assessing suspected COVID-19 pneumonia and in outpatient settings. Several sites reported adoption of written policies on use of CT in COVID-19 pneumonia and preferential use of chest radiography over chest CT. About 29% of the patients (225/782) had 2-8 chest CT exams in less than one month. Multiphase scan protocols and their association with higher radiation dose were concerning in 11/54 healthcare sites from 4/28 countries in our study.

Healthcare sites varied CT protocols: some adopted a single-phase, non-contrast protocol and performed only one chest CT exam, some used reduced-dose chest CT protocol, and, likewise, some reduced radiation dose for follow-up chest CT compared with the baseline exam.

Only 1/28 countries reported median CTDIvol <3mGy for chest CT exams. Conversely, lower dose chest CT exams on newer scanners (installed between 2016-2020) and those with iterative reconstruction suggest proper scanner use.

Use of CT in most sites participating in our study was compliant with guidance from several notable organizations and societies which discourage use of screening CT in absence of paucity of RT-PCR or serological assays [13] [14] [15] [16] [17] . Conversely, our study identified several areas of concern including those stemming from frequent report on the use of CT for initial diagnosis of suspected COVID-19 pneumonia. Although CT is justified in high disease prevalence sites I n P r e s s with low availability of antigen or antibody assays for the coronavirus, overuse of CT remains an important concern. Although recommendations from the Fleischner Society support use of CT for follow-up and complications in COVID-19 pneumonia, they do not provide guidance on frequency of its use, specific scan protocols and the need to reduce dose for follow-up CT examinations [16] .

Use of contrast-enhanced chest CT is justified in patients with suspected vascular complications and superimposed necrotizing infection, however, most other pulmonary opacities in COVID-19 pneumonia can be assessed with a single-phase, non-contrast phase chest CT. As opposed to abdomen-pelvis CT, there is little justification for multiphase CT of the chest for most clinical indications in and beyond COVID-19 pneumonia [8, 18] .

There are no specific recommended or target doses in patients with COVID-19

pneumonia, but when evaluation is limited to lung parenchyma, a CTDIvol <3mGy, as recommended for low dose chest CT for lung cancer screening may be sufficient for COVID-19 pneumonia [8] . There are studies on use of high-resolution and ultra-high-resolution chest CT in patients with COVID-19 pneumonia, most studies related to acquisition technique for scanning these patients describe use of non-contrast reduced-dose CT protocol [10, [19] [20] [21] [22] . These studies describe use of high-pitch, selective photon shield with tin filter, low tube current and/or tube potential to obtain low-dose CT without loss of diagnostic information related to COVID-19 pneumonia [20] . However, several fold variations in CTDIvol and DLP in chest CT exams at participating sites in our study often from the same country and city makes dose optimization difficult. Another cause of concern pertains to higher CTDIvol associated with scanners installed between 2011 and 2015 as compared with older scanners prior to 2011. Such differences in CTDIvol (about 3mGy) might not clinically meaningful and might be related to variations in I n P r e s s patient sizes, protocol types, scan parameters. These differences highlight the importance of CT protocol optimization, which is as important as access to latest scanners and dose reduction technologies.

Differences in DLP associated with chest CT across sites could be related to differences in CTDIvol, scan range (particularly, in the inferior anatomic coverage of lung base versus adrenal glands), and/or number of acquired scan phases. This implies an urgent need for optimization of scan protocols and radiation doses for chest CT examinations and not only limited to imaging of patients with COVID-19 pneumonia.

Our study has limitations. Some clinical indications or usage of CT might have been missed due to the limited sample size of 10-20 patients per site. The study was also a retrospective data collection on practices and protocols related to use of CT in patients with COVID-19 pneumonia. Not all healthcare sites and countries participated, so generalization was limited. The accuracy of our results is subject to errors and variations in manually recorded data from different sites. Due to logistic and data privacy issues, we did not obtain CT image datasets or assess image quality with different CT protocols used at the participating sites. We lacked data on clinical features and disease severity, particularly from sites with multiple follow-up CT examinations. Therefore, we could not assess the justification of follow-up CT exams in patients with COVID-19 pneumonia. We could not adequately assess justification of multiple CT exams in some patients since the provided information stated follow-up or worsening of symptoms.

Also, we did not obtain RT-PCR results due to the anticipated lack of access to these tests and their results at several sites, particularly from the developing countries. Also, there was a relative heterogeneity in the number of patients contributed by each site based on disease prevalence and availability and access to data at the time of the ongoing pandemic.

In summary, our international, multicenter study on practices, protocols and radiation doses suggests frequent CT usage in assessment of disease severity, complications, and followup in patients with COVID-19 with a several fold variations in number of scan phases, CT examinations per patient, and associated radiation dose descriptors. We identify an urgent need for a dedicated task force to establish specific guidelines and recommendations on the frequency of CT and specific scan protocols to minimize the effects of cumulative radiation exposure from multiple CT and multiphase CT protocols. I n P r e s s 

Critical Supply Shortages -The Need for Ventilators and Personal Protective Equipment during the Covid-19 Pandemic

Leveraging open hardware to alleviate the burden of COVID-19 on global health systems

Younger ages at risk of Covid-19 mortality in communities of color

Counting the cost of COVID-19

Estimated effectiveness of symptom and risk screening to prevent the spread of COVID-19

Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy

Chest CT practice and protocols for COVID-19 from radiation dose management perspective

Low-dose CT in COVID-19 outbreak: radiation safety, image wisely, and image gently pledge

Recommendation of low-dose CT in the detection and management of COVID-2019

Frequency and Distribution of Chest Radiographic Findings in Patients Positive for COVID-19

Can Lung US Help Critical Care Clinicians in the Early Diagnosis of Novel Coronavirus (COVID-19) Pneumonia?

ACR-Position-Statements/Recommendations-for-Chest-Radiography-and-CT-for-Suspected-COVID19-Infection

Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19)

Clinical Management of COVID-19 (Spanish)

The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society

CT protocols and radiation doses for hematuria and urinary stones: Comparing practices in 20 countries

Ultra-high-resolution computed tomography can demonstrate alveolar collapse in novel coronavirus (COVID-19) pneumonia

Proposal of a low-dose, long-pitch, dualsource chest CT protocol on third-generation dual-source CT using a tin filter for spectral shaping at 100 kVp for CoronaVirus Disease 2019 (COVID-19) patients: a feasibility study

Application of CareDose 4D combined with Karl 3D technology in the low dose computed tomography for the follow-up of COVID-19

Chest CT features of coronavirus disease 2019 (COVID-19) pneumonia: key points for radiologists

While many people took part in the project, only principal contributors were included as coauthors. We would like to express our gratitude to the following contributors for their help: 

I n P r e s s C26 10 61 (23) 77 (50) 11 11 13 (7) 415 (189) I n P r e s s Note. I n P r e s s